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ABSTRACT
INTRODUCTION Persons with multiple risk factors of cardiovascular disease (CVD) are at a greater risk 
than persons exposed to a single risk factor. Control of specific risk factors of CVD in Poland is rather 
poor. Effective control of comorbid hypertension and hypercholesterolemia seems especially challenging.
OBJECTIVES The aim of the study was to assess the control of hypertension and hypercholesterolemia 
in patients with both hypertension and hypercholesterolemia; data from the Polish multicenter national 
health survey, WOBASZ II, were analyzed.
PATIENTS AND METHODS The WOBASZ II study was a cross ­sectional survey conducted from 2013 to 
2014 in 6170 people (3410 women and 2760 men) from all 16 Polish voivodships.
RESULTS Age ­standardized prevalence of coexisting hypertension and hypercholesterolemia in WOBASZ 
II sample was 34.6%. The prevalence of hypercholesterolemia in participants with hypertension was 
69.7%. Age ­standardized rates of control of hypertension, hypercholesterolemia, and both hypertension 
and hypercholesterolemia in the entire analyzed age range of 19 to 99 years was 24.3%, 11.2%, and 
5.4%, respectively. In multivariable logistic regression models, control of both hypertension and hyper­
cholesterolemia was associated with smoking (odds ratio [OR], 0.5; 95% CI, 0.34–0.76), cardiovascular 
disease (OR, 2.25; 95% CI, 1.70–2.97), frequent medical visits (OR, 1.76; 95% CI, 1.33–2.32), and high 
education level (OR, 1.37; 95% CI, 1.03–1.80).
CONCLUSIONS Comorbid hypertension and hypercholesterolemia were observed in one ­third of the Polish 
population (included in WOBASZ II study). Only 5.4% have both risk factors controlled. After adjust­
ment for covariates, female sex, nonsmoking, comorbid CVD or diabetes, the frequency of medical 
visits, and high level of education appeared to increase the proportion of controlled hypertension or 
hypercholesterolemia.
EDITORIAL
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Patients with multiple CVD risk factors are 
at higher risk of incident CVD than persons ex-
posed to only 1 risk factor. The CVD risk result-
ing from concomitant hypertension and hyper-
cholesterolemia is typically greater than the sum 
of risk from individual exposure to hyperten-
sion or hypercholesterolemia alone.16,17 It was 
found that in patients with hypertension and 
concomitant hyperlipidemia, the risk of CVD 
doubles, and in patients with normal choles-
terol levels, the coexistence of hypertension re-
sults in a 3-fold increase in the risk of CVD.14 In 
people with SBP of 195 mm Hg and TC level of 
8.5 mmol/l, the risk of CVD increases as much as 
9 -fold.18 Data on men aged 35 to 64 years from 
the POL -MONICA (Polish part of the Monitor-
ing of Trends and Determinants in Cardiovascu-
lar Disease) study showed that the coexistence of 
hypertension and hypercholesterolemia increases 
the risk of death caused by CHD over 4.5 -fold.19 
The assessment of the overall cardiac risk can be 
made using the Systematic Coronary Risk Evalu-
ation (SCORE) tables. For example, in the Polish 
population, a nonsmoking 70 -year -old man with 
SBP of 180 mm Hg and TC of 8 mmol/l has a 50% 
risk of cardiovascular death within 10 years, and, 
respectively, with SBP of 120 mm Hg and TC of 
4 mmol/l, only 10%.20
Results of the analyses in the Polish popula-
tion published so far do not indicate to what ex-
tent exposure to hypertension and hypercholes-
terolemia occurs in the same person.
The objectives of the study were: 1) to assess 
the prevalence of comorbid hypertension and hy-
percholesterolemia in participants of the nation-
wide WOBASZ II study; 2) to assess the preva-
lence of hypercholesterolemia in the Polish hyper-
tensive population; 3) to evaluate the control of 
blood pressure and cholesterol levels in patients 
with hypertension and hypercholesterolemia; 
and 4) to assess the factors related to the control.
PATIENTS AND METHODS The WOBASZ II study 
was a cross -sectional survey conducted from 
2013 to 2014 in 6170 people (3410 women and 
2760 men) from all 16 voivodships (108 com-
munes) in Poland. The reporting rate was 45.5%. 
The sampling method used a 3 -stage scheme, 
stratified by voivodship, commune category, and 
sex. The study was approved by the Ethics Com-
mittee at the Institute of Cardiology in Warsaw, 
Poland (no. 1344). Each respondent was informed 
in writing about the purpose of the study and 
the range of activities (including blood pressure 
measurements and blood collection for laborato-
ry tests). All participants signed informed con-
sent form. The study methods have been pre-
sented in detail elsewhere.21 Blood pressure was 
measured 3 times in 1 visit in a sitting position 
in accordance with the 2013 European Society of 
Cardiology / European Society of Hypertension 
guidelines22 and the 2015 Polish Society of Hy-
pertension23 guidelines. An UA631(AND Co., To-
kyo, Japan) automatic device was used. The mean 
INTRODUCTION In the Polish population, ac-
cording to the WOBASZ II (Multicenter Nation-
al Population Health Examination Survey; Polish, 
Wieloośrodkowe Ogólnopolskie Badanie Stanu 
Zdrowia Ludności), the prevalence of hyperten-
sion in adults above 20 years of age is 46% and 
40% and the prevalence of dyslipidemia is 70% 
and 64.3% in men and women, respectively.1,2
In the 2011 Polish NATPOL (Arterial hyper-
tension and other CVD risk factors in Poland; 
Polish, Nadciśnienie Tętnicze oraz inne czynni-
ki ryzyka chorób serca i naczyń w Polsce) study, 
in the general population aged 18 to 79 years, 
the prevalence of hypercholesterolemia was es-
timated at 61.1% and the efficacy of treatment 
(achieving total cholesterol [TC] <4.9 mmol/l) 
at 10.9%.3 In POLFOKUS, another Polish study, 
elevated level of low -density lipoprotein choles-
terol (LDL -C) was observed in 49.2%, 61.6%, and 
61.5% patients with controlled, uncontrolled, and 
resistant hypertension, respectively.4 The preva-
lence of other modifiable risk factors for cardio-
vascular disease in the WOBASZ II study popu-
lation was described elsewhere.5-8
The Framingham study showed that the inci-
dence of CVD increases 2- to 3 -fold in patients 
with hypertension—with the highest risk of 
stroke, heart failure, and all forms of coronary 
heart disease (CHD): angina pectoris, myocardi-
al infarction, sudden cardiac death. In patients 
aged 40 to 69 years, mortality due to stroke 
or CHD doubled with each increase in systolic 
blood pressure (SBP) of 20 mm Hg and diastol-
ic blood pressure (DBP) of 10 mm Hg.9 A rela-
tionship with CVD risk was seen in a wide range 
of TC and LDL-C concentrations. This applies 
to men and women, both with and without di-
agnosed CVD.10 It has been proved that chang-
es in SBP in the range of 110 to 170 mm Hg are 
associated with an approximately 6 -fold in-
crease in CHD risk. Similarly, an increase in TC 
level in the range of 4.0 to 8.0 mmol/l results 
in an approximately 8 -fold increase in the risk 
of CHD. And an increase in the range of 110 to 
170 mm Hg SBD and 70 to 105 mm Hg DBP 
also increases the risk of stroke nearly 8 -fold.11 
The implementation of antihypertensive treat-
ment reduces the risk of CHD by approximately 
25%.12 The inclusion of lipid -lowering treatment 
in patients with hypertension reduces the re-
sidual risk of CHD by more than 35%,13 as con-
firmed by the AFCAPS/TexCAPS (Air Force / Tex-
as Coronary Atherosclerosis Prevention Study)14 
and the ASCOTLLA (AngloScandinavian Cardi-
ac Outcomes Trial -Lipid Lowering Arm) study.15
WHAT’S NEW?
This is the first study based on the latest and largest Polish epidemiological 
WOBASZ II surbey regarding the prevalence of hypercholesterolemia and 
hypertension in the Polish population, the prevalence of hypercholesterolemia 
in patients with hypertension, control of blood pressure and cholesterol levels, 
and factors affecting this control.
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or beer in the last 12 months at least once?” High 
education was defined as more than vocation-
al education. Obesity was defined as body mass 
index (BMI) of 30 kg/m2 or higher; overweight, 
as BMI of 25 to 30 kg/m2; and normal weight, 
as BMI of less than 25 kg/m2. High income in-
come per person in the household of more than 
1000 PLN (>250 EUR).
Statistical analyses Continuous variables such 
as blood pressure values and age were present-
ed as arithmetic mean (95% CI). Concentrations 
of TC, LDL -C, HDLC, and TG were presented as 
median and (95% CI). Qualitative variables were 
presented as percentages (95% CI). Crude preva-
lence of hypertension and hypercholesterolemia, 
and the prevalence of both hypertension and hy-
percholesterolemia control were described as 
percentages (95% CI) for the following age rang-
es 20 to 49, 50 to 59, 60 to 69, 70 to 79, and 80 
years and older. The results were standardized25 
for age of the Polish population based on data 
from the Central Statistical Office report of De-
cember 31, 2014. The standardization method 
has been described in detail earlier.21 The prev-
alence of the analyzed features was compared 
using the χ2 test for trend. The influence of var-
ious parameters (age, sex, BMI, diabetes, HDL -C 
concentration, TG concentration, smoking, al-
cohol consumption, education, physical activi-
ty, coexisting CVD, marital status, the SCORE, 
number of visits and income) on the control of 
blood pressure, hypercholesterolemia, and si-
multaneous control of both blood pressure and 
hypercholesterolemia was evaluated by univar-
iate logistic regression. The influence of select-
ed parameters on the control of hypertension, 
hypercholesterolemia, and simultaneous control 
of both hypertension and hypercholesterolemia 
was evaluated by multivariable logistic regres-
sion with adjusted odds ratios. The logistic re-
gression model took into account the simultane-
ous influence of age (increase by 10 years), HDL-
-C and TG concentrations (increase by 1mmol/l) 
as well as sex, diabetes, obesity, smoking, coexis-
tence of other cardiovascular diseases, frequency 
of visits (<4 visits a year vs ≥4 visits a year), lev-
el of education (vocational education vs second-
ary and higher), and income (above 1000 PLN 
vs below 1000 PLN). All statistical tests were 
2 -tailed, and significance was accepted for P val-
ues of less than 0.05. The statistical analysis was 
performed with Statistica 12.5 (StatSoft Inc., 
Tulsa, Oklahoma, United States), Excel (Micro-
soft Corp., Seattle, Washington, United States), 
and PQStat (PQStat Software, Poznań, Poland).
RESULTS The  analysis included 5939 par-
ticipants aged 19 to 99 years (2647 men and 
3292 women). A total of 231 people with no 
measurements of blood pressure or cholester-
ol levels were excluded from the analysis. Mean 
(SD) age was 49.5 (16.3) years (men, 48.9 [16.3] 
years; women, 50.0 [16.3] years).
of the second and third measurements was used 
for analysis. Clinical chemistry tests were per-
formed at the Central Laboratory “Diagnostyka” 
at the Institute of Cardiology in Warsaw, which 
has been certified by the Centre for Disease Con-
trol – Lipid Standardization Program in Atlanta, 
United States, and has the European quality cer-
tificate, Random International Quality Assess-
ment Scheme. The sequence of procedures was 
as follows: first, blood pressure measurements 
were performed, then the survey was taken, and 
finally, blood was collected for laboratory tests. 
Details of the methodology for measuring blood 
pressure, blood collection, and clinical chemistry 
tests have been described elsewhere.1,2
Hypertension was defined as SBP of 140 mm Hg 
or higher, or DBP of 90 mm Hg or higher, or use 
of blood pressure -lowering medication (regularly 
for the last 2 weeks). Hypercholesterolemia was 
diagnosed if TC levels were 5 mmol/l or high-
er, or LDL -C levels were 3 mmol/l or higher, or 
the participant was taking a lipid -lowering med-
ication (regularly for the last 2 weeks). Treated 
hypertension was defined as patients with hy-
pertension who reported taking medication for 
high BP (affirmative response to the question, 
“Have you taken these medicines regularly dur-
ing the last 2 weeks?”). Treated hypercholester-
olemia was defined as patients who reported tak-
ing medication for high cholesterol level (affir-
mative response to the question, “Have you tak-
en these medicines regularly during the last 2 
weeks?”). Controlled hypercholesterolemia was 
defined as patients with hypercholesterolemia 
who had TC of less than 5 mmol/l and LDL -C of 
less than 3 mmol/l for people with intermediate 
or low cardiovascular risk; LDL-C of less than 
2.5 mmol/l for people with high CVD risk; LDL-C 
of less than 1.8 mmol/l for people with very high 
CVD risk. The target treatment thresholds have 
been adopted according to risk categories based 
on the 2016 European guidelines for CVD preven-
tion in clinical practice.24 Controlled hyperten-
sion was defined as patients with hypertension 
who had SBP of less than 140 mm Hg and DBP of 
less than 90 mm Hg. CVD risk was assessed ac-
cording to the SCORE risk charts as follows: less 
than 1%, low risk; from 1% up to 5%, interme-
diate risk; from 5% up to 10%, high score; 10% 
and higher, very high risk. Diabetes was defined 
as patients who gave an affirmative response to 
the question, “Have you ever been diagnosed with 
diabetes?” or those taking a hypoglycemic med-
ication (regularly for the last 2 weeks). Smoking 
was defined as at least 1 cigarette per day. Comor-
bid CVD was defined as previously diagnosed cor-
onary artery disease, past myocardial infarction, 
myocardial revascularization, previous stroke, 
peripheral atherosclerosis. Physical activity was 
defined as at least 30 minutes of uninterrupted 
activity, for example, a walk, gymnastic exercis-
es at least 4 d/wk. Alcohol drinkers were defined 
as patients who gave an affirmative response to 
the question, “Have you drunk any vodka, wine 
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and in men aged 60 to 69 years (76.2% [95% CI, 
71.9–80.6]) (TABLE 4).
Among patients with coexisting hyperten-
sion and hypercholesterolemia, the highest con-
trol rate of hypertension, hypercholesterolemia, 
and both hypertension and hypercholesterolemia 
(crude data) was observed in patients older than 
80 years of age (37.7%, 29.2%, and 17%, respec-
tively). Age -standardized control of hyperten-
sion, hypercholesterolemia, and both hyperten-
sion and hypercholesterolemia in the entire sam-
ple (age range,19–99 years) was 24.3%, 11.2%, and 
5.4%, respectively (TABLE 5).
Age, comorbid diabetes, comorbid CVD, fre-
quent medical visits, and CVD risk according to 
the SCORE of less than 5% were positively asso-
ciated with controlled hypertension, hypercholes-
terolemia, and both. Female sex, obesity, income 
above 250 EUR per person in the household were 
not associated with controlled hypercholesterol-
emia, but related with controlled hypertension 
and a controlled both hypertension and hyper-
cholesterolemia. Education higher than vocational 
In the whole WOBASZ II population, hyperten-
sion was found in 2784 (crude data 46.9%) per-
sons (1365 men and 1419 women). Mean (SD) 
age was 58.4 (13.9) years (men, 55.8 [14.4] years; 
women, 60.9 [13.0]).
Comorbid hypertension and hypercholesterol-
emia was found in 2037 patients (982 men and 
1055 women). Mean age was 58.8 (12.9) years 
(men, 56.1 [13.4] years; women, 60.5 [11.8] years). 
Descriptive statistics of the study group are sum-
marized in TABLES 1 and 2.
Age -standardized prevalence of coexisting hy-
pertension and hypercholesterolemia in WOBASZ 
II population was 32.2% (95% CI, 30.8–33.7); in 
men, 34.5% (95% CI, 32.3–36.7); and in women, 
31% (95% CI, 29.1–32.9) (TABLE 3).
Age -standardized prevalence of hypercholester-
olemia in patients diagnosed with hypertension 
in the entire study sample was 69.7% (95% CI, 
65.9–73.4); in men, 70% (95% CI, 64.9–75.2); and 
in women, 68.6% (95% CI, 63.1–74.2). The highest 
prevalence (crude data) was observed in women 
aged 50 to 59 years (83.3% [95% CI, 79.6–87.1]) 
TABLE 1 Descriptive characteristics of participants with hypertension and hypercholesterolemia in WOBASZ II Study
Variable Hypertension and hypercholesterolemia
Age, y, mean (95% CI); n 58.8 (58.2–59.3); 2037
Male sex, mean (95% CI); n 48.3 (45.1–51.4); 982
BMI kg/m2, % (95% CI); n 17.3 (13.4–21.3); 353
SBP, mm Hg, mean (95% CI); n 144.7 (143.8–145.5); 2037
DBP, mm Hg, mean (95% CI); n 86.2 (85.7–86.7); 2037
TC, mmol/l, median (95% CI); n 5.6 (5.5–5.6); 2012
LDL ­C, mmol/l, median (95% CI); n 3.5 (3.4–3.6); 2008
HDL ­C, mmol/l, median (95% CI); n 1.4 (1.3–1.4); 2009
TG, mmol/l, median (95% CI); n 1.5 (1.4–1.6); 2010
Hypertension treatment, % (95% CI); n 59 (56.2–61.7); 1201
Hypercholesterolemia treatment, % (95% CI); n 31.3 (27.7–34.9); 637
Diabetes, % (95% CI); n 14 (10.0–18.0); 286
Smoking, % (95% CI); n 21.7 (17.9–25.6); 443
Alcohol drinkers, % (95% CI); n 80.3 (78.4–82.2); 1636
Education, % (95% CI); n 75.2 (73–77.4); 15,32
Physical activity, % (95% CI); n 56.9 (54–59.7); 1159
Coexisting CVD, % (95% CI); n 27.6 (23.9–31.3); 562
Married, % (95% CI); n 23.7 (19.9–27.5); 483
SCORE, % (95% CI); n <5% 54.6 (51.7–57.5); 1112
≥5% and <10% 26.9(23.1–30.6); 547
≥10% 18.6(14.6–22.5); 378
Visits, number/year, % 
(95% CI); n
0 11.3 (7.2–15.4); 230
1 25.6 (21.8–29.3); 521
2–4 25.9 (22.2–29.7); 528
5–6 7 (2.8–11.2); 143
>7 30.2 (26.6–33.8); 615
Income, % (95% CI); n <1000 PLN (<250 EUR) 43 (39.5–46.5); 453
>1000 PLN (>250 EUR) 57 (53.9–60.1); 998
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; LDL­C, low ­density 
lipoprotein cholesterol; HDL­C, high ­density lipoprotein cholesterol; SBP, systolic blood pressure; SCORE, Systematic 
Coronary Risk Evaluation; TC, total cholesterol; TG, triglycerides
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comorbid CVD, frequent medical visits, and high 
education. Smoking decreased the odds of con-
trolled of both hypertension and hypercholester-
olemia 2 -fold (FIGURE 1; Supplementary material, 
Tables S1 and S2).
DISCUSSION Our results suggest that about one-
-third of the adult population have comorbid hy-
pertension and hypercholesterolemia. Control of 
hypertension in this group appeared similar to 
the control in the general population, but con-
trol of hypercholesterolemia was better than in 
the general population.1,2 Nevertheless, propor-
tion of patients with good control of both condi-
tions was only about 5%.
Considering the more stringent thresholds 
of antihypertensive treatment in accordance 
was associated only with improvement in hyper-
tension. Conversely, smoking was associated with 
worse control of hypertension, hypercholesterol-
emia, and both. Alcohol consumption was inverse-
ly associated with controlled hypertension (TABLE 6).
After adjustment for covariates, female sex, 
comorbid CVD, frequent medical visits, and high 
education increased the odds of controlled hyper-
tension. The strongest effect was observed for co-
morbid CVD (odds ratio, 2.35; 95% CI, 1.93–2.86). 
Hypercholesterolemia control was positively re-
lated with comorbid diabetes, CVD, and with con-
trolled hypertension. Hypercholesterolemia con-
trol was inversely related with smoking (odds 
ratio, 0.57; 95% CI, 0.45–0.71). The good con-
trol of both hypertension and hypercholester-
olemia was more frequent in participants with 
TABLE 2 Descriptive characteristics of patients with hypertension and hypercholesterolemia in WOBASZ II Study
Variable Controlled hypertension 
and 
hypercholesterolemia
Controlled hypertension; 
uncontrolled 
hypercholesterolemia
Controlled 
hypercholesterolemia; 
uncontrolled 
hypertension
Uncontrolled 
hypertension and 
hypercholesterolemia
Age, y, mean (95% CI); n 64.1 (62.4–65.7); 151 57.3 (56–58.5); 411 46 (45.4–46.6); 171 58 (48–66); 1275
Male sex, % (95% CI); n 39.1 (26.6–51.5); 59 38 (30.3–45.6); 156 44.4 (33.3–55.6); 76 53.4 (49.7–57.2); 681
BMI kg/m2, % 
(95% CI); n
<25 13.9 (–0.9 to 28.7); 21 15.1 (6.2–24); 62 9.4 (0–23.6); 16 19.7 (14.8–24.6); 251
25–30 41.7 (29.5–53.9); 63 44 (36.8–51.2); 181 42.7 (31.3–54); 73 45.6 (41.6–49.7); 582
>30 44.4 (32.5–56.3); 67 40.9 (33.4–48.3); 168 48 (37.1–58.8); 82 34.7 (30.2–39.1); 442
SBP, mm Hg, mean (95% CI); n 124.3 (122.7–125.9); 151 144.2 (142.8–145.6); 411 120.2 (119.7–120.6); 171 149 (141.5–161.5); 1275
DBP, mm Hg, mean (95% CI); n 75.8 (74.4–77.1); 151 85.9 (85.1–86.7); 411 76.1 (75.7–76.4); 171 90.5 (84.5–96.5); 1275
TC, mmol/l, median, (95% CI); n 4.1 (3.9–4.2); 151 5.7 (5.5–5.8); 411 4.1 (3.8–4.4); 171 5.9 (5.8–5.9); 1275
LDL ­C, mmol/l, median, (95% CI); n 2.1 (2–2.2); 151 3.6 (3.5–3.7); 411 2.1 (2–2.2); 171 3.7 (3.7–3.8); 1274
HDL ­C, mmol/l, median, (95% CI); n 1.2 (1.2–1.3); 151 1.3 (1.3–1.4); 411 1.3 (1.1–1.4); 171 1.4 (1.4–1.4); 1275
TG, mmol/l, median, (95% CI); n 1.3 (1.1–1.4); 150 1.6 (1.5–1.7); 411 1.3 (1–1.5); 171 1.6 (1.5–1.6); 1274
Hypertension treatment, % (95% CI); n 100 (100–100); 151 100 (100–100); 411 77.2 (70–84.4); 132 37.7 (33.4–42.1)’ 481
Hypercholesterolemia treatment, % 
(95% CI); n
100 (100–100); 151 27.3 (19–35.5); 112 95.9 (92.9–98.9); 164 14.3 (9.2–19.4); 182
Diabetes, % (95% CI); n 23.8 (9.9–37.8); 36 14.6 (5.7–23.5); 60 26.9 (14.1–39.7); 46 10.7 (5.6–15.9); 137
Smoking, % (95% CI); n 9.9 (0–25.1); 15 19.2 (10.5–27.9); 79 12.3 (0–26.3); 21 25.5 (20.8–30.2); 352
Alcohol drinkers, % (95% CI); n 81.5 (74.6–88.3); 123 74 (69–78.9); 304 80.1 (73.4–86.8); 137 82.7 (80.5–85); 1055
Education, % (95% CI); n 68.9 (60–77.8); 104 75.7 (70.9–80.4); 311 68.4 (60–76.8); 117 77 (74.4–79.7); 982
Physical activity, % (95% CI); n 55 (44.3–65.7); 83 55.7 (49.3–62.2); 229 58.5 (48.8–68.1); 100 57.3 (53.7–60.9); 731
Coexisting CVD, % (95% CI); n 55.6 (45–66.3); 84 33.6 (25.7–41.5); 138 50.9 (40.4–61.4); 874 18.8 (13.9–23.8); 240
Married, % (95% CI); n 30.5 (17.2–43.8); 46 23.1 (14.6–31.6); 95 31 (18.5–43.4); 53 21.9 (17–26.7); 279
SCORE, % 
(95% CI); n
SCORE ≥5 72.8 (64.5–81.2); 110 71.8 (66.2–77.3); 254 55 (43.9–66.1); 77 51.9 (47.8–56.1); 556
SCORE ≥5% 
and <10
9.9 (0–25.1); 15 27.1 (18.2–36); 96 43.6 (31.1–56); 61 34.8 (30–39.7); 373
SCORE ≥10% 17.2 (2.7–31.7); 26 1.10–11.5); 4 1.4 (0–17.9); 2 13.3 (7.7–18.8); 142
Visits, 
number/
year, % 
(95% CI); n
0 16.6 (2–31.1); 25 14.6 (5.7–23.5); 60 34.5 (22.4–46.6); 59 9 (3.8–14.3); 115
1 2.6 (0–18.4); 4 8.3 (0–17.5); 34 9.9 (0–24.2); 17 36.4 (32–40.8); 464
2–4 24.5 (10.6–38.4); 37 27 (18.7–35.3); 111 4.7 (0–19.3); 8 26.1 (21.4–30.8); 333
5–6 14.6 (0–29.3); 22 8.5 (0–17.8); 35 4.7 (0–19.3); 8 5.8 (0.5–11.1); 74
>7 41.7 (29.5–53.9); 63 41.6 (34.2–49); 171 46.2 (35.2–57.2); 79 22.7 (17.8–27.5); 289
Income, % 
(95% CI); n
<PLN 1000 
(< EUR 250)
42.6 (29.9–55.4); 58 41.3 (33.5–49.1); 152 35.1 (22.2–48.1); 52 45 (40.5–49.4); 482
> PLN 1000 
(> EUR 250)
57.4 (46.4–68.3); 78 58.7 (52.1–65.3); 216 64.9 (55.3–74.4); 96 55 (51–59.1); 59
Abbreviations: see TABLE 1
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years of age, below 140/80 mm Hg; and for those 
over 80 years of age, below 150/80 mm Hg), 
blood pressure control in the WOBASZ II pop-
ulation would decrease from 23% to approx-
imately 14%, and simultaneous control of 
with the 2018 European Society of Hyperten-
sion guidelines26 and the 2019 Polish Society 
of Hypertension guidelines27 (for patients be-
low 65 years of age, the target pressure below 
130/80 mm Hg; for those between 65 and 85 
TABLE 3 Crude and age ­standardized prevalence of hypertension and hypercholesterolemia in the Polish population 
aged 19–99
Age group, y Total Men Women
19–49 15 (13.7–16.3); 432 20.9 (18.8–23.1); 278 9.9 (8.4–11.4); 154
50–59 46.7 (44–49.5); 596 50.9 (46.7–55.1); 278 43.7 (40.1–47.2); 320
60–69 58.2 (55.2–61.2); 613 58.3 (53.9–62.7); 280 58.1 (54.1–62.2); 333
70–79 60.4 (56–64.8); 290 56.6 (49.8–63.4); 116 63.3 (57.6–69); 174
≥80 52 (45.1–58.8); 106 41.6 (30.6–52.6); 32 58.3 (49.7–66.8); 74
Age standardized 32.2 (30.8–33.7), 2037 34.5 (32.3–36.7); 982 31 (29.1–32.9); 1055
Data are presented as percentage (95% CI); number of patients.
TABLE 4 Crude and age ­standardized prevalence of hypercholesterolemia in the Polish hypertensive population 
aged 19–99
Age group, y Total Men Women
19–49 64.9 (61.2–68.5); 666 67.3 (62.8–71.8); 413 60.9 (54.9–66.9); 253
50–59 79.9 (77–82.8); 746 76.2 (71.9–80.6); 362 83.3 (79.6–87.1); 384
60–69 77.6 (74.7–80.5); 790 77.3 (73–81.7); 362 77.8 (73.9–81.7); 428
70–79 71.3 (66.9–75.7); 407 69.5 (62.5–76.4); 167 72.5 (66.9–78.1); 240
≥80 60.9 (53.7–68.2); 174 53.3 (40.7–66); 60 64.9 (56.2–73.7); 114
Age standardized 69.7 (65.9–73.4); 2037 70 (64.9–75.2); 982 68.6 (63.1–74.2); 1055
Data are presented as percentage (95% CI); number of patients.
TABLE 5 Crude and age ­standardized prevalence of controlled blood pressure, hypercholesterolemia, or both in the Polish population with 
hypertension and hypercholesterolemia aged 19–99
Population Age group, y P value 
for 
trend
19–49 50–59 60–69 70–79 ≥80 Age 
standardized
Controlled hypertension
Total 18.8 (15.1–22.4); 
81
30.5 (26.8–34.2); 
182
31.6 (28–35.3); 
194
27.6 (22.4–32.7); 
80
37.7 (28.5–47); 
40
24.3 (21.7–26.9); 
557
<0.001
Men 16.2 (11.9–20.5); 
45
25 (19.9–30.1); 
69
26.1 (20.9–31.2); 
73
20.7 (13.3–28.1); 
24
25 (10–40);  
8
19.7 (16.5–22.9)a; 
219
0.01
Women 23.4 (16.7–30.1); 
36
35.3 (30.1–40.5); 
113
36.3 (31.2–41.5); 
121
32.2 (25.2–39.1); 
56
43.2 (32–54.5); 
32
29.5 (25.1–33.9); 
358
<0.001
Controlled hypercholesterolemia
Total 4.9 (2.8–6.9);  
21
14.1 (11.3–16.9); 
84
20.9 (17.7–24.1); 
128
20 (15.4–24.6); 
58
29.2 (20.6–37.9); 
31
11.2 (9.7–12.7); 
322
<0.001
Men 6.5 (3.6–9.4);  
18
15.6 (11.3–19.9); 
43
15.7 (11.5–20); 
44
19 (11.8–26.1); 
22
25 (10–40);  
8
10.8 (8.6–13)b; 
135
<0.001
Women 1.9 (0–4.1);  
3
12.8 (9.2–16.5); 
41
25.2 (20.6–29.9); 
84
20.7 (14.7–26.7); 
36
31.1 (20.5–41.6); 
23
11 (9.1–12.8); 
187
<0.001
Controlled hypertension and hypercholesterolemia
Total 2.3 (0.9–3.7);  
10
7.4 (5.3–9.5);  
44
9.3 (7–11.6);  
56
7.6 (4.5–10.6); 
22
17 (9.8–24.1); 
18
5.4 (4.3–6.4); 
151
<0.001
Men 2.9 (0.9–4.8);  
8
6.5 (3.6–9.4);  
18
6.8 (3.8–9.7);  
19
9.5 (4.2–14.8); 
11
9.4 (–0.7 to 19.5); 
3
4.7 (3.3–6.1)c; 
59
0.09
Women 1.3 (0–3.1);  
2
8.1 (5.1–11.1); 
26
11.4 (8–14.8);  
38
6.3 (2.7–9.9);  
11
20.3 (11.1–29.4); 
15
5.7 (4.3–7.1); 
92
<0.001
Data are presented as percentage (95% CI); number of patients.
a Men vs women (P <0001);   b Men vs women (P = 0.95);   c Men vs women (P = 0.79)
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Comparing our results with a large epidemio-
logical study conducted in the United States from 
2005 to 2010, NHANES (National Health and 
Nutrition Examination Survey), we found that 
the participants from the United States achieved 
the goal of lipid -lowering therapy more than 
4 -fold more often (11.2% vs 45.4%, respective-
ly). Moreover, control of both hypertension and 
hypercholesterolemia was 6 -fold more common 
than in our study (30.7% vs. 5.4%, respective-
ly).31 These comparisons might indicate the gap in 
the effectiveness of risk factors control between 
Poland and the United States. However, the ob-
served difference could also be explained by larg-
er prevalence of obesity, diabetes, and lower prev-
alence of smoking in the NHANES sample. Our 
results indicate that these factors seem to im-
prove hypertension and hypercholesterolemia 
control. The iSEARCH (Cardiovascular Risk Fac-
tors and Microalbuminuria in Hypertensive In-
dividuals) study, which included over 17 000 pa-
tients from 26 countries with treated hyperten-
sion, found lower prevalence of hypercholester-
olemia (average 49%) than observed in our study. 
However, there was a large variation in hypercho-
lesterolemia prevalence in different regions—
the lowest prevalence was observed in Southern 
Europe (43.3%) and Asia (43.1%), and the high-
est, in North America (64.4%), the Middle East 
(56.1%), and Northern Europe (53%).32 In the Pol-
ish POSTER (Therapeutic Strategies in Poorly 
Controlled Hypertension in Outpatient Setting in 
Poland) study, which enrolled 8766 patients with 
poorly controlled hypertension, the prevalence of 
hypercholesterolemia was estimated at 64.8%.33
Our results are in accordance with findings from 
Polish part of the EUROASPIRE IV (European Soci-
ety of Cardiology study of lifestyle, risk factors, and 
treatment approaches in patients with coronary 
hypercholesterolemia and blood pressure would 
only be achieved in 3.5% of patients.
Treatment targets for hypertension or hyper-
cholesterolemia were more frequently achieved in 
women, participants with high education, non-
smokers, persons with comorbid CVD or diabe-
tes, and in those who had more medical visits.
Some caution is recommended in the inter-
pretation of the results of the present study 
due to relatively low (approximately 45.5%) 
participation rate which could have affected 
the representativeness of the sample. In previ-
ous WOBASZ II analysis, it was found that re-
gional differences in the prevalence of hyper-
cholesterolemia were related to the participa-
tion rate (0.4% increase in the percentage of 
people with hypercholesterolemia per 1% in-
crease in reporting rate).2 Such relationship 
was not observed in case of hypertension prev-
alence.1 Moreover, our participation rates were 
similar to that recorded in other European stud-
ies, for example, the EHES (European Health 
Examination Survey) conducted from 2009 to 
2012, in which the reporting rate ranged from 
16% to 57% in men and from 31% to 74% in 
women.28 However, it is likely that low response 
rate might have contributed to some underes-
timation in the prevalence rates.29,30
Moreover, cross -sectional study design does 
not allow to address the problem of causality. 
Although multivariate models allow to control 
the effect of important covariates, residual con-
founding is still possible.
Nevertheless, the study has strengths. In con-
trast to most of the evidence collected in patients 
from the clinics, our study involved a large na-
tionwide sample. Moreover, the research team 
applied standardized research procedures to en-
sure highest possible data quality.
TABLE 6 Univariate odds ratios and 95% CI of factors associated with control of hypertension, hypercholesterolemia, or both in patients with 
hypertension and hypercholesterolemia in the WOBASZ II study
Variable Controlled hypertension Controlled hypercholesterolemia Controlled hypertension and 
hypercholesterolemia
Age, per 10 years 1.22 (1.15–1.3) 1.06 (1–1.13) 1.31 (1.2–1.43)
Sex (female) 1.72 (1.45–2.04) 1.17 (1–1.38) 1.48 (1.16–1.88)
BMI (>30 kg/m2) 1.31 (1.1–1.55) 1.17 (0.99–1.38) 1.36 (1.07–1.74)
Diabetes 1.39 (1.1–1.74) 1.75 (1.4–2.18) 1.73 (1.28–2.33)
HDL ­C, per 1.0 mmol/l 0.94 (0.48–1.84) 1.62 (0.9–2.93) 1.44 (0.67–3.1)
TG, per 1.0 mmol/l 0.87 (0.54–1.4) 0.63 (0.33–1.18) 0.73 (0.29–1.83)
Smokers 0.61 (0.49–0.76) 0.56 (0.45–0.69) 0.41 (0.28–0.6)
Alcohol drinkers 0.98 (0.96–0.99) 0.99 (0.99–1) 0.98 (0.96–1)
Education 1.2 (1.01–1.42) 1.01 (0.86–1.19) 1.1 (0.86–1.39)
Physical activity 1.02 (0.87–1.21) 0.89 (0.75–1.04) 1.04 (0.82–1.33)
Coexisting CVD 2.33 (1.95–2.78) 2.15 (1.81–2.56) 3.01 (2.36–3.83)
Married 1.06 (0.88–1.29) 1.19 (0.99–1.44) 1.16 (0.88–1.52)
SCORE (<5%) 1.72 (1.45–2.04) 1.62 (1.37–1.91) 2.08 (1.61–2.69)
Data are presented as odds ratio (95% CI).
Abbreviations: see TABLE 1
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In our study, in participants with comorbid hy-
pertension and hypercholesterolemia, we found 
that blood pressure control was low and compa-
rable to the general population (23% vs 24.3%), 
artery disease) study, which showed better control 
of hypertension and hypercholesterolemia in pa-
tients after hospitalization due to CHD34 compared 
with the findings from the general population.1,2
FIGURE 1 Multivariable odds ratios and 95% CI for clinical variables associated with control of hypertension (A), hypercholesterolemia (B), or both (C) 
Abbreviations: see TABLE 1
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Examination Survey (WOBASZ II study): assumptions, methods, and imple­
mentation. Kardiol Pol. 2016; 7: 681­690.
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